Anti-amyloid immunotherapy has been proposed as an appropriate therapeutic approach for Alzheimer's disease (AD). Significant efforts have been made towards the generation and assessment of antibody-based reagents capable of preventing and clearing amyloid aggregates as well as preventing their synaptotoxic effects. In this study, we selected a novel set of human anti-amyloid-beta peptide 1-42 (Aβ1-42) recombinant monoclonal antibodies in a single chain fragment variable (scFv) and a single-domain (VH) format. We demonstrated that these antibody fragments recognize in a specific manner amyloid-beta deposits in APP/Tg mouse brains, inhibit toxicity of oligomeric Aβ1-42 in neuroblastoma cell cultures in a concentration-dependent manner and reduced amyloid deposits in APP/Tg2576 mice after intracranial administration. These antibody fragments recognize epitopes in the middle/C-terminus region of Aβ, which makes them strong therapeutic candidates due to the fact that most of the Aβ species found in the brains of AD patients display extensive N-terminus truncations/modifications.
Introduction
The accumulation of extracellular and intracellular amyloid-beta (Aβ) peptide aggregates in the human brain has been hypothesized to play a central role in the neuropathology of Alzheimer's disease (AD) (Haass and Selkoe, 2007; La Ferla et al., 2007; Walsh and Selkoe, 2007) . Anti-Aβ immunotherapy has been shown to disrupt Aβ aggregates, block aggregation, attenuate toxicity, as well as promote the clearance of the peptide in the central nervous system (CNS) in animal models. Immunotherapy approaches, both active immunization with Aβ peptide and passive transfer of anti-Aβ antibodies, have shown therapeutic efficacy in several amyloid precursor protein transgenic (APP/Tg) mouse models, which develop AD-like amyloid plaque pathology (Schenk et al., 1999; Bard et al., 2000; Janus et al., 2000; Hartman et al., 2005; Morgan, 2006; Brody and Holtzman, 2008) , as well as in canine and primate models of amyloidosis (Lemere et al., 2004 , Head et al., 2008 . However, active immunization in human clinical trials resulted in the development of brain inflammation in some patients (Munch and Robinson, 2002; Gilman et al., 2005; Holmes et al., 2008) .
The hypothesis that passive antibody immunotherapy could be more appropriate as a therapeutic approach for AD promoted efforts towards the generation and application of antibody-based reagents capable of preventing and clearing amyloid deposits as well as preventing their synaptotoxic effects and increasing structural plasticity of dendritic spines (Bard et al. However, there are reports that passive immunization also may show adverse side effects, such as, vasogenic edema, microhemorrhages and increased vascular amyloid angiopathy observed after administration of mouse monoclonal anti-Aβ antibodies in transgenic mice (Pfeifer et al., 2002; Lee et al., 2005) . Efforts have been made to generate antibodies recognizing other linear or conformational epitopes within Aβ1-42 that may be biologically functional without being associated with the development of adverse events. This could be achieved, for example, by using phage displayed recombinant antibody (Ab) fragment libraries that results in the generation of a panel of specific antibodies quickly, Journal of Neuroimmunology 223 (2010) 104-114 
